Effects of Helicobacter pylori Treatment on Incidence of Gastric Cancer in Older Individuals

• Published in: Gastroenterology (New York, N.Y. 1943) Vol. 155; no. 1; pp. 67 - 75
• Main Authors: Leung, Wai K., Wong, Irene O.L., Cheung, Ka Shing, Yeung, Kar Fu, Chan, Esther W., Wong, Angel Y.S., Chen, Lijia, Wong, Ian C.K., Graham, David Y.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2018
• Subjects: Adult; Aged; Amoxicillin - therapeutic use; Antacids - therapeutic use; Anti-Bacterial Agents - therapeutic use; Antibiotics; Bacteria; Bismuth - therapeutic use; Chemoprevention; Clarithromycin - therapeutic use; Drug Therapy, Combination; Female; Helicobacter Infections - drug therapy; Helicobacter Infections - epidemiology; Helicobacter pylori; Hong Kong - epidemiology; Humans; Incidence; Levofloxacin - therapeutic use; Male; Middle Aged; Protective Factors; Proton Pump Inhibitors - therapeutic use; Registries; Retrospective Studies; Risk Factors; Stomach Cancer; Stomach Neoplasms - epidemiology; Hong Kong; Stomach Cancer; CDARS; Antibiotics; Chemoprevention; CI; Bacteria; SIR
• DOI: 10.1053/j.gastro.2018.03.028
• ISSN: 0016-5085; 1528-0012

Although eradication of Helicobacter pylori infection reduces the risk of gastric cancer, few data are available on its effects in older subjects. We compared the age-specific risk of gastric cancer in a large cohort of subjects who received H pylori eradication therapy vs a matched general population. We searched the Hospital Authority database of Hong Kong to identify individuals with H pylori infection who had received a course of clarithromycin-containing eradication therapy from January 2003 through December 2012. We compared the gastric cancer incidence in this cohort with the expected incidence for the local general population by retrieving the gastric cancer incidence of the age- and sex-matched population from 2003 through 2014 (the latest available year) from the Hong Kong Cancer Registry. The primary outcome was the incidence of gastric cancer development in the cohort treated for H pylori infection vs the expected number of gastric cancer cases in the general population. Analyses were conducted by a priori age groups of less than 40 years, 40–59 years, and 60 years or older. Among 73,237 subjects infected with H pylori who received eradication therapy, 200 (0.27%) developed gastric cancer during a median follow-up time of 7.6 years. Compared with the matched general population, the gastric cancer risk was significantly lower in subjects 60 years or older who had received H pylori treatment (standardized incidence ratio [SIR], 0.82; 95% confidence interval [CI], 0.69–0.97; P = .02) but not in younger groups. When data were stratified based on time from H pylori treatment (less than 5 years, 5–9 years, and 10 or more years), the risk of gastric cancer was significantly lower than the general population 10 or more years after eradication in the group 40–59 years old (SIR 0.32; 95% CI, 0.08–0.88; P = .04) and the group 60 years or older (SIR, 0.42; 95% CI, 0.42–0.84; P = .02) than the other age groups. In an analysis of data from a public hospital database on Hong Kong, we associated treatment of H pylori infection with a lower risk of gastric cancer, particularly in older subjects, 10 or more years after treatment. [Display omitted]